EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
about
Maximal testosterone suppression in the management of recurrent and metastatic prostate cancerOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.Artesunate suppresses the viability and mobility of prostate cancer cells through UCA1, the sponge of miR-184Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer.Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy : A national survey on patterns of practice.The value of multimodality imaging in the investigation of a PSA recurrence after radical prostatectomy in the Irish hospital setting.(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomesInvestigational serine/threonine kinase inhibitors against prostate cancer metastases.Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.Therapy assessment in prostate cancer using choline and PSMA PET/CT.Concurrent treatment with simvastatin and NF-κB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-κB/LIN28/let-7 miRNA signaling pathway.Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer.Does T1- and diffusion-weighted magnetic resonance imaging give value-added than bone scintigraphy in the follow-up of vertebral metastasis of prostate cancer?Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells.Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.Correlation between postoperative prostate-specific antigen and biochemical recurrence in positive surgical margin patients: Single surgeon series.Positive surgical margins and biochemical recurrence following minimally-invasive radical prostatectomy - An analysis of outcomes from a UK tertiary referral centre.Early or delayed radiotherapy after prostatectomy-who really benefits?Roundup.Estrogen receptor β, a regulator of androgen receptor signaling in the mouse ventral prostate.Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer: a Cochrane systematic review.Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer.Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?Reduced number of CD169+ macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients.
P2860
Q29994552-96851479-3970-494F-85BF-65E7ABF18D0FQ30235173-C74660E9-38F3-4E3F-B659-17EC57B556E4Q32173730-0F5C9EF1-733C-41BF-B84C-AC0E2A67215DQ33441176-9497507D-973D-4C7F-B29C-C1ABA1B1ED75Q33566906-8C8F3CCE-2B06-4962-A54A-A3882F4B6045Q33622362-B2F29A4E-3D29-4FAB-827B-6AA621641E1BQ33653836-6D98B12D-8DC4-4047-91EA-0FF16D0C5379Q36407003-288B377F-8A0A-4E66-BF26-E950981AB880Q38611750-E750A9A6-0141-437F-8403-5658A9FEDFE5Q38618888-6E2F4E1B-2304-402A-B027-10E24D5D80A9Q38620741-770EFC79-0555-47FA-95CC-95C1297E5DCAQ38638855-7D560031-D3F8-46E0-95C2-EE692559DFB6Q38653262-FD2848C5-FCF4-4200-998E-247593494593Q38658856-7C7FC9B7-7312-442C-AD0D-3CE7CDB7C10FQ38705877-F989E658-E1F2-4BEF-B352-FA37F565E184Q38726659-ED6DB1C1-8081-448C-B0C5-934490BDD686Q38747415-9B52F24B-292A-479F-9BF6-9AD970D38E1FQ38756919-F9ED927B-80FD-4BFA-A40C-75003ED371C7Q38821290-C3EE00DB-F746-4E76-B65E-BAECFD742B2FQ38837262-CB1E7B6C-61EA-4912-A899-F8D93B2C9ECEQ39021945-4B723631-4505-4F9E-A82B-7D2C4310335CQ39051286-A849D07E-1F56-44EE-A706-CC33C67FEE37Q39242140-AF5C35B2-7E7E-450F-95BF-19B3A2B11B30Q39328036-E24EC2E4-1F0A-40EA-81C6-0FFAC98CD0B2Q41070980-392F6098-44C3-4F56-A4D4-649B70362CF2Q41472411-740F2865-C28B-4862-87D2-99BBDE820B0AQ41485921-FEB5370D-47F8-4535-9307-5979E5F4E078Q41566010-A4E49C0C-6922-4F9F-85B8-B08375A6A488Q41708911-D2CA6A8A-A695-42CD-A904-4F7318853CDDQ41957391-F34CBAE9-2BBB-411F-AC57-7F81A92A8949Q42062124-271266B2-A298-415D-9C44-CA55959DE3E1Q42284813-A8857875-EFD3-4D16-8706-DC6221C72E2FQ42332346-405509C6-4C88-48ED-9ED7-B2292F9EAC75Q42361436-D37BA5F0-83AA-422E-A814-D7B54CAC8B1BQ42508857-95B00C2F-798F-4A13-9C4B-878F87FB2C25Q42698718-7F6D870D-E7DA-48A8-B022-14BC8C5815F2Q43092220-19830FF8-0323-4154-833A-8742EB59A2E0Q47097602-570DC60A-0403-4578-B44E-A09026A14809Q47109138-40A1DC42-2031-459B-9E7A-5B46F3B9D5E8Q47112998-25F7C6FE-4802-49B5-9AAE-930DA77338FF
P2860
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
EAU-ESTRO-SIOG Guidelines on P ...... ion-Resistant Prostate Cancer.
@en
EAU-ESTRO-SIOG Guidelines on P ...... ion-Resistant Prostate Cancer.
@en-gb
type
label
EAU-ESTRO-SIOG Guidelines on P ...... ion-Resistant Prostate Cancer.
@en
EAU-ESTRO-SIOG Guidelines on P ...... ion-Resistant Prostate Cancer.
@en-gb
prefLabel
EAU-ESTRO-SIOG Guidelines on P ...... ion-Resistant Prostate Cancer.
@en
EAU-ESTRO-SIOG Guidelines on P ...... ion-Resistant Prostate Cancer.
@en-gb
P2093
P50
P1433
P1476
EAU-ESTRO-SIOG Guidelines on P ...... ion-Resistant Prostate Cancer.
@en
P2093
Erik Briers
Henk G van der Poel
Joaquim Bellmunt
Malcolm D Mason
Maria De Santis
Michel Bolla
Nicolas Mottet
Olivier Rouvière
Philip Cornford
Theo H van der Kwast
P304
P356
10.1016/J.EURURO.2016.08.002
P407
P577
2016-08-31T00:00:00Z